Translational research progress in malignant lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 74-75, 2017.
Article
in Zh
| WPRIM
| ID: wpr-505853
Responsible library:
WPRO
ABSTRACT
Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma (B-NHL),but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug.Recently,many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma.The advances in translational research field were summarized in this manuscript.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Leukemia & Lymphoma
Year:
2017
Type:
Article